Diagnostic methods for thrombotic thrombocytopenic purpura

Thrombotic thrombocytopenic purpura (TTP) is a rare but life-threatening condition characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and end-organ damage due to platelet-rich blood clots in microvessels.Most TTP cases are acquired and are caused by autoantibodies inhibiting plasma ADAMTS13.In this text, our primary focus is to review the diagnostic techniques employed in identifying cases of TTP.Diagnosing TTP relies on clinical judgment and laboratory tests.The most commonly presented symptoms are related to end-organ damage and include neurological, gastrointestinal, renal, and thrombocytopenia-related symptoms.Not all TTP cases exhibit critical illness, and suspicion may require a complete blood count.The diagnostic strategies include clinical prediction tools like the FRENCH and PLASMIC scores that help guide the initial stages of treatment, and rapid ADAMTS13 activity measurement is the definitive diagnostic method.ADAMTS-13 deficiency is a key TTP marker.It is a metalloprotease primarily synthesized in the liver, regulating thrombogenesis by cleaving von Willebrand factor.Its deficiency distinguishes TTP, with levels ≤ 10% considered diagnostic.Dysfunction can result from inhibitors or congenital mutations.Autoantibodies are a common cause, with genetic risk markers identified in some cases.Testing involves enzyme-linked immunosorbent assay and rapid assays.Regular testing during and after treatment helps assess disease activity and relapse risk, with activity levels ≤ 10% indicating a higher risk of relapse and the need for prophylactic therapy.